At a glance
ClinicalIndex Comparison RecordN/ACompleted· 207 enrolled
Drug / intervention
vascular graftsdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Safety and Primary Patency Between FUSION Vascular Graft With Bioline and EXXCEL Soft ePTFE (FINEST)
In Brief
A clinical study evaluating vascular grafts for Peripheral Arterial Occlusive Disease. Completed, enrolled 207 participants across 25 sites in 3 countries.
Detailed Summary
To demonstrate the patency and safety of vascular grafts: EXXCEL and FUSION Bioline.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Occlusive Disease
CountriesCzechia, Germany, United States
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartMay 2010
Primary CompletionDec 2012
Study CompletionJun 2013
TodayJul 2026
First PostedApr 30, 2010
Enrollment StartMay 17, 2010
Primary CompletionDec 18, 2012
Study CompletionJun 4, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 16.2 years ago
Interventions
vascular graftsdevice
All devices will be used to treat patients with peripheral arterial occlusive disease